Why Evolus, Inc.’s (EOLS) Stock Is Down 6.77%
As of Thursday, September 10, Evolus, Inc.’s EOLS share price has dipped by 6.77%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Commentary & Analysis
Why Evolus, Inc.’s (EOLS) Stock Is Up 15.70%
As of Thursday, August 06, Evolus, Inc.’s EOLS share price has surged by 15.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Evolus, Inc.’s (EOLS) Stock Is Up 20.47%
As of Thursday, August 06, Evolus, Inc.’s EOLS share price has surged by 20.47%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Evolus, Inc.'s Q3 Earnings
Evolus, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (EOLS) missed or beat analyst's expectations.Michael Rose
Why Evolus, Inc.’s (EOLS) Stock Is Down 5.77%
As of Friday, July 10, Evolus, Inc.’s EOLS share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | EOLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $525.8 | $550.7 | 38% |
|
| Shares Out (Mil) | 65.9 | 42.5 | 54% |
|
| Institutional Ownership | 85.4% | 84.5% | 53% |
|
| Float (Mil) | 47.6 | 45.7 | 46% |
|
| Beta | 1.43 | 0.73 | 80% |
|
| Avg Daily Volume (000s) | 631 | 448 | 60% |
|
| Price Change (52-week) |
33.1% | 61.4% | 75% |
|
| Growth | EOLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 39.4% | 6.1% | 93% |
|
| Net Income (5yr) | 20.6% | (1.4%) | 74% |
|
| EPS (5yr) | 30.2% | 15.1% | 81 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.3%) | (15.0%) | 37% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.060) | ($0.048) | $0.293 | |
| Month Ago EPS | ($0.060) | ($0.042) | $0.276 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 2 | |
| Three Months Ago EPS | ($0.070) | ($0.094) | $0.240 | |
| Year/Year Chg | (50.8%) | (94.0%) | (191.8%) | |
| Financials | EOLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $317 | $317 | 36% |
|
| Net Income (TTM) (Mil) | ($34) | ($11) | 19% |
|
| EPS (TTM) | ($0.527) | ($0.700) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($7) | 17% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $5 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $162 | $6 | 48% |
|
| Enterprise Value (Q1) (Mil) | $639 | $493 | 36% |
|
| Valuation | EOLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.40 | na |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | EOLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.4% | 69.4% | 78% |
|
| Net Margin | (10.8%) | 2.0% | 21% |
|
| ROA | (14.4%) | (22.2%) | 23% |
|
| ROE | 138.6% | (22.8%) | 97% |
|
| Liabilities to Assets | 112.5% | 32.5% | 96% |
|
| F-Score | 3 | 3 | 18% |
|
Evolus, Inc. did not pass any screens on 9/28/2026.
